Abstract
Arsenic containing treatments have a history of over two millenniums. Recently, arsenic trioxide (As 2 O 3 ) has been introduced into the treatment of both de novo and relapsed acute promyelocytic leukemia (APL), with remarkable clinical success. Several investigations using both freshly isolated APL blast cells as well as APL-derived tumor cell lines have shown that the main mechanism by which As 2 O 3 exerts its antileukemic activity in APL is induction of apoptosis in the leukemic cell population. Recently, it has become evident that the apoptotic effects of As 2 O 3 are not restricted to APL cells but may also be observed in malignant cells of non-APL origin. In the present review, history, current clinical use as well as future perspectives of As 2 O 3 therapy in both hematologic and solid malignancies are discussed, with special emphasis being put on the potential future role of As 2 O 3 in the treatment of non-APL tumors. Of particular importance, enhancing agents suited to increase As 2 O 3 -sensitivity in less sensitive tumors (e.g. ascorbic acid) are also addressed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
